Phase I clinical trial of the bispecific antibody MDX-H210 (anti_FcgrammaRI x anti-HER-2/neu in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer.

Translated title of the contribution: Phase I clinical trial of the bispecific antibody MDX-H210 (anti_FcgrammaRI x anti-HER-2/neu in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer.

R. Repp, H.H. van Ojik, T. Valerius, G. Groenewegen, G. Wieland, C. Oetzel, B. Stockmeyer, W.-D. Becker, M. Eisenhut, H. Steininger, Y.M. Deo, G.H. Blijham, J.R. Kalden, J.G.J. van de Winkel, M. Gramatzki

Research output: Contribution to journalArticleAcademicpeer-review

Translated title of the contributionPhase I clinical trial of the bispecific antibody MDX-H210 (anti_FcgrammaRI x anti-HER-2/neu in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer.
Original languageUndefined/Unknown
Pages (from-to)2234-43
Number of pages10
JournalBritish Journal of Cancer
Volume15
Issue number89
Publication statusPublished - 2003

Keywords

  • Econometric and Statistical Methods: General
  • Geneeskunde (GENK)
  • Geneeskunde(GENK)
  • Algemeen onderzoek
  • Bescherming en bevordering van de menselijke gezondheid
  • Immunology
  • Internal medicine

Cite this